welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that target enrollment has been achieved for the company’s pivotal Phase 3 clinical trial, CPP FAP-310, evaluating CPP-1X/sulindac in adults with familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
Desmoid Tumors: Clinical Features and Treatment Options for Advanced DiseaseDesmoid tumors describe a rare monoclona...
-
Different Surgical Strategies in the Treatment of Familial Adenomatous Polyposis: What’s the Role of the Ileor...Prophylactic (procto-) colectomy is the ...
-
New Clinical Trials Offer Hope in Two Rare Genetic DiseasesIn 1994, three of Cindy Parseghian’s f...
-
Body Image, Cosmesis, Quality of Life, and Functional Outcome of Hand-Assisted Laparoscopic Versus Open Restorative ...BACKGROUND : This study aimed to compare...
-
Regression of Colonic Adenomas After Treatment with Sulindac in Familial Adenomatous Polyposis: A Case with a 2-Year...Familial adenomatous polyposis (FAP) is ...
-
Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous PolyposisImportance Patients with familial aden...
-
A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Rofecoxib, a Selective Cyclooxygenase-2 Inhib...PURPOSE : The aim of this study was to e...